Merlin分层恶性胸膜间皮瘤一线化疗后Defactinib对比安慰剂维持治疗:COMMAND双盲随机II期研究
该全球双盲随机安慰剂对照II期研究纳入至少4周期一线化疗后疾病控制的晚期恶性胸膜间皮瘤患者344例,按merlin分层后1:1随机接受口服defactinib(n=173)或安慰剂(n=171)维持治疗。defactinib组中位PFS 4.1个月(95%CI 2.9-5.6)vs 安慰剂组4.0个月(95%CI 2.9-4.2),中位OS 12.7个月(95%CI 9.1-21)vs 13.6个月(95%CI 9.6-21.2),HR 1.0(95%CI 0.7-1.4)。结论认为defactinib未能改善merlin低表达患者的PFS或OS,不能推荐作为晚期MPM维持治疗。
要点
- defactinib组中位PFS 4.1个月 vs 安慰剂组4.0个月,中位OS 12.7个月 vs 13.6个月,HR 1.0(95%CI 0.7-1.4)。
- merlin低表达与高表达患者中,两组间缓解率、PFS、OS及生活质量均无统计学差异。
- 常见≥3级不良事件为恶心、腹泻、乏力、呼吸困难及食欲下降。
核心结论
- 在merlin低表达恶性胸膜间皮瘤患者中,一线化疗后defactinib维持治疗未改善PFS或OS。
- defactinib不能推荐作为晚期恶性胸膜间皮瘤的维持治疗。
研究设计与样本
- 全球、双盲、随机、安慰剂对照II期试验。
- 纳入至少4周期一线化疗后疾病控制的晚期恶性胸膜间皮瘤患者。
- 按merlin分层后1:1随机接受口服defactinib或安慰剂,直至疾病进展、不可接受毒性或退出。
- 共344例患者随机分配至defactinib组(n=173)或安慰剂组(n=171)。
- 共同主要终点为PFS和OS,采用肺癌症状量表-间皮瘤工具评估生活质量。
主要发现
- defactinib组中位PFS 4.1个月(95%CI 2.9-5.6)vs 安慰剂组4.0个月(95%CI 2.9-4.2)。
- defactinib组中位OS 12.7个月(95%CI 9.1-21)vs 安慰剂组13.6个月(95%CI 9.6-21.2),HR 1.0(95%CI 0.7-1.4)。
- merlin低表达患者较merlin高表达患者两组生存均更短,但两治疗组间缓解率、PFS、OS及生活质量无统计学差异。
- 最常见≥3级不良事件为恶心、腹泻、乏力、呼吸困难及食欲下降。
关键数值与推荐
- defactinib组中位PFS 4.1个月(95%CI 2.9-5.6)vs 安慰剂组4.0个月(95%CI 2.9-4.2)。
- defactinib组中位OS 12.7个月(95%CI 9.1-21)vs 安慰剂组13.6个月(95%CI 9.6-21.2),HR 1.0(95%CI 0.7-1.4)。
临床怎么用
- defactinib不能推荐作为晚期恶性胸膜间皮瘤的维持治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Inhibition of focal adhesion kinase has been shown to selectively kill mesothelioma cells that express low levels of moesin-ezrin-radixin-like protein (merlin). On this basis, we designed a randomized, phase II trial to investigate whether defactinib as maintenance therapy after standard first-line chemotherapy could improve progression-free survival (PFS) in patients with malignant pleural mesothelioma (MPM). METHODS: This global, double-blind, randomized, placebo-controlled trial was conducted in patients with advanced MPM and disease control after at least four cycles of first-line chemotherapy. Patients were stratified for merlin and then randomly assigned (in a 1:1 fashion) to receive either oral defactinib or placebo until disease progression, unacceptable toxicity, or withdrawal occurred. The coprimary end points were PFS and overall survival (OS). Quality of life (QoL) was assessed using the Lung Cancer Symptom Scale for Mesothelioma tool. RESULTS: Three hundred forty-four patients were randomly assigned to receive either defactinib (n = 173) or placebo (n = 171). The median PFS was 4.1 months (95% CI, 2.9 to 5.6 months) for defactinib versus 4.0 months (95% CI, 2.9 to 4.2 months) for placebo. The median OS was 12.7 months (95% CI, 9.1 to 21 months) for defactinib versus 13.6 months (95% CI, 9.6 to 21.2 months) for placebo (hazard ratio, 1.0; 95% CI, 0.7 to 1.4). Although shorter survival for both defactinib- and placebo-treated patients was observed, in the patients who had merlin-low MPM compared with the patients who had merlin-high MPM, there were no statistical differences in response rate, PFS, OS, or QoL between the treatment groups. The most common grade 3 or worse adverse events were nausea, diarrhea, fatigue, dyspnea, and decreased appetite. CONCLUSION: Neither PFS nor OS was improved by defactinib after first-line chemotherapy in patients with merlin-low MPM. Defactinib cannot be recommended as maintenance therapy for advanced MPM.
引用
- Fennell DA, Baas P, Taylor P, et al. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019. PMID: 30785827. doi:10.1200/JCO.2018.79.0543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。